News
J.P. Morgan analyst Anne E. Samuel reiterated the Neutral rating on Premier, Inc. (NASDAQ:PINC) on Tuesday, with a price ...
Leerink Partnrs also issued estimates for CorMedix’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.16 EPS, Q4 2025 earnings at $0.29 EPS, FY2025 earnings at $0.73 EPS, FY2026 earnings at ...
Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (LSE:0A4D) from Outperform to Market Perform. There are 35 funds or institutions reporting positions ...
Leerink Partners handhaafde dinsdag hun positieve kijk op de aandelen van Zura Bio Ltd. (NASDAQ: ZURA) met een herhaalde Outperform-rating en een koersdoel van $ 12,00. Volgens InvestingPro data ...
Leerink Partners heeft maandag hun financiële vooruitzichten voor Lexeo Therapeutics (NASDAQ:LXEO) bijgesteld, waarbij het koersdoel werd verlaagd naar $ 18 van $ 19, terwijl het aandeel als ...
Shattuck Labs, Inc. (NASDAQ:STTK – Free Report) – Analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Shattuck Labs in a report released on Monday, March 17th.
Hosted on MSN21d
Leerink Partners Downgrades Elevation Oncology (ELEV)Fintel reports that on March 21, 2025, Leerink Partners downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from Outperform to Market Perform. Analyst Price Forecast Suggests 2,468.35% ...
Leerink Partners analyst Thomas Smith reiterated a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of $52.00. The company’s shares closed yesterday at $19.69 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback